corneal endothelial disease

Actionable Insights Powered by AI

Alcon Secures Control of Aurion Biotech in Strategic Takeover

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute